CorticorpNews
Back to Finance
Expand

Image: CNBC Top News

Updated

Hims & Hers launched compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, CNBC Top News reported on November 18, 2026. None of the compounded treatments is approved by the FDA, and the company acknowledged there is more to learn about their efficacy.

1 outlet · 1 article · first seen Nov 18, 10:10 AM ET

What this touches in markets

Stored closes for the instruments tied to this story's tags and places, with their dates.

  • HIMS closed at 17.55, down 5.44%, on 2026-11-17. Listed for: ticker the story is tagged with.
  • XLV closed at 185.24, down 1.41%, on 2026-11-17. Listed for: Health Care sector ETF.

Every source article